Zhang Tao, Huang Wei-Sen, Guan Weijie, Hong Ziying, Gao Jiabo, Gao Guoying, Wu Guofeng, Qin Yin-Yin
Nanshan School, Guangzhou Medical University, Guangzhou, China.
School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
J Thorac Dis. 2020 Dec;12(12):7429-7441. doi: 10.21037/jtd-20-1743.
Since December 2019, the pneumonia cases infected with 2019 novel coronavirus have appeared, posing a critical threat to global health. In this study, we performed a meta-analysis to discover the different clinical characteristics between severe and non-severe patients with COVID-19 to find the potential risk factors and predictors of this disease's severity, as well as to serve as a guidance for subsequent epidemic prevention and control work. PubMed, Cochrane Library, Medline, Embase and other databases were searched to collect studies on the difference of clinical characteristics of severe and non-severe patients. Meta-analysis was performed using RevMan 5.3 software, and the funnel plots could be made to evaluate the publication bias. P>0.05 means no statistical significance. Furthermore, a meta-regression analysis was performed by using Stata 15.0 to find the potential factors of the high degree of heterogeneity (I>50%). Sixteen studies have been included, with 1,172 severe patients and 2,803 non-severe patients. Compared with non-severe patients, severe patients were more likely to have the symptoms of dyspnea, hemoptysis, and the complications of ARDS, shock, secondary infection, acute kidney injury, and acute cardiac injury. Interestingly, the former smokers were more prevalent in severe cases as compared to non-severe cases, but there was no difference between the two groups of 'current smokers'. Except for chronic liver disease and chronic kidney disease, the underlying comorbidities of hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary disease (COPD), malignancy, cerebrovascular disease, and HIV can make the disease worse. In terms of laboratory indicators, the decreased lymphocyte and platelet count, and the increased levels of white blood cell (WBC), D-dimer, creatine kinase, lactate dehydrogenase, procalcitonin, alanine aminotransferase, aspartate aminotransferase, and C-reactive protein were more prevalent in severe patients. Meta-regression analysis showed that patient age, gender, and proportion of severe cases did not significantly impact on the outcomes of any clinical indexes that showed high degree of heterogeneity in the meta-analysis. In conclusion, the severity of COVID-19 could be evaluated by, radiologic finding, some symptoms like dyspnea and hemoptysis, some laboratory indicators, and smoking history, especially the ex-smokers. Compared with non-severe patients, severe patients were more likely to have complications and comorbidities including hypertension, cardiovascular disease etc., which were the risk factors for the disease to be severer, but the chronic liver disease and chronic kidney disease were not associated the severity of COVID-19 in China.
自2019年12月以来,出现了感染2019新型冠状病毒的肺炎病例,对全球健康构成了严重威胁。在本研究中,我们进行了一项荟萃分析,以发现COVID-19重症和非重症患者之间的不同临床特征,寻找该疾病严重程度的潜在风险因素和预测指标,并为后续的疫情防控工作提供指导。检索了PubMed、Cochrane图书馆、Medline、Embase等数据库,以收集关于重症和非重症患者临床特征差异的研究。使用RevMan 5.3软件进行荟萃分析,并可制作漏斗图以评估发表偏倚。P>0.05表示无统计学意义。此外,使用Stata 15.0进行荟萃回归分析,以找出异质性程度较高(I>50%)的潜在因素。纳入了16项研究,其中重症患者1172例,非重症患者2803例。与非重症患者相比,重症患者更易出现呼吸困难、咯血症状,以及ARDS、休克、继发感染、急性肾损伤和急性心脏损伤等并发症。有趣的是,与非重症病例相比,既往吸烟者在重症病例中更为普遍,但两组“当前吸烟者”之间没有差异。除慢性肝病和慢性肾病外,高血压、糖尿病、心血管疾病、慢性阻塞性肺疾病(COPD)、恶性肿瘤、脑血管疾病和HIV等基础合并症会使病情加重。在实验室指标方面,重症患者淋巴细胞和血小板计数降低,白细胞(WBC)、D-二聚体、肌酸激酶、乳酸脱氢酶、降钙素原、丙氨酸转氨酶、天冬氨酸转氨酶和C反应蛋白水平升高更为普遍。荟萃回归分析表明,患者年龄、性别和重症病例比例对荟萃分析中显示高度异质性的任何临床指标的结果均无显著影响。总之,COVID-19的严重程度可通过影像学表现、呼吸困难和咯血等一些症状、一些实验室指标以及吸烟史(尤其是既往吸烟者)来评估。与非重症患者相比,重症患者更易出现包括高血压、心血管疾病等在内 的并发症和合并症,这些是疾病加重的危险因素,但慢性肝病和慢性肾病与中国COVID-19的严重程度无关。